Clinical Trials
9 trialsNCT07307443 2025-12-29
A Phase II Study of Anlotinib and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Lung Cancer.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT05400070 2024-10-18
Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC
Tang-Du Hospital
Phase 2 Active not recruiting
NCT06048315 2023-09-21
A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody
Qianfoshan Hospital
Phase 3 Not yet recruiting
NCT04790409 2023-09-14
Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations
Zhejiang Cancer Hospital
Phase 2 Completed
NCT04731909 2021-02-10
Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung Cancer
Third Military Medical University
Phase NA Unknown
NCT03983928 2019-08-15
Study of TQB2450 Combined With Anlotinib in the Treatment of Mutation Positive Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Unknown
NCT03780283 2018-12-21
Efficacy and Safety of Anlotinib as Maintenance Treatment After First-line Chemotherapy in SCLC
First Hospital of Shijiazhuang City
Phase 2 Unknown
NCT03765775 2018-12-06
Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative
First Hospital of Shijiazhuang City
Phase 2 Unknown
NCT03589950 2018-07-18
Anlotinib Plus Chemotherapy for Patients With Advanced Non-small Cell Lung Cancer
The First People's Hospital of Lianyungang
Phase 2 Unknown